<i>In Vitro</i> Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015
James A. Karlowsky(University of Manitoba), Patricia A. Bradford(Inorganic Specialists (United States)), Boudewijn L. M. de Jonge(Pfizer (United States)), Meredith Hackel, Krystyna M. Kazmierczak(Indiana University Bloomington), Daniel F. Sahm(Micro Focus (United States))
Cited by 190
Related Papers
β-Lactams and β-Lactamase Inhibitors: An Overview
|Cold Spring Harbor Perspectives in Medicine|2016|1.3k
Prevalence in the United States of <i>aac(6</i> ′ <i>)</i> - <i>Ib</i> - <i>cr</i> Encoding a Ciprofloxacin-Modifying Enzyme
|Antimicrobial Agents and Chemotherapy|2006|749
Multiple-Drug Resistant Enterococci: The Nature of the Problem and an Agenda for the Future
|Emerging infectious diseases|1998|732
Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States
|Annals of Clinical Microbiology and Antimicrobials|2006|384
Trends in Antimicrobial Resistance among Urinary Tract Infection Isolates of <i>Escherichia coli</i> from Female Outpatients in the United States
|Antimicrobial Agents and Chemotherapy|2002|369